RxDoctor Payments Data

Marcus Griffin, MD

Internal Medicine · Kihei, HINPI 1780774174

Payments from drug & device makers

$1,186in general payments, 2019–2025

Across 42 payments — averaging $28.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$506
  • Novo Nordisk$221
  • Pfizer$129
  • Bayer$76
  • AbbVie$63
  • GSK$35
  • plus $155 from 8 others

What the payments were for

  • Food & beverage$1,03888%
  • Education$14812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,186 in reported general payments places this provider in the 70th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$134,432
Medicare patients
129
Services billed
1,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$42,966
EliquisApixaban22$29,993
Atorvastatin Calcium181$3,778
Lisdexamfetamine Dimesylate12$3,352
Ezetimibe53$2,354
Eszopiclone14$2,259
Famotidine101$2,129
Rosuvastatin Calcium79$1,786
Escitalopram Oxalate65$1,477
Amlodipine Besylate114$1,439
PaxlovidNirmatrelvir/Ritonavir20$1,429
Gabapentin99$1,393
Memantine Hcl36$1,318
Esomeprazole Magnesium17$1,310
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$221$42,96628 claims
PfizerEliquis, Paxlovid$129$31,42342 claims
AbbVieSynthroid$63$86012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Kihei

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →